#### **EXPRESS MAIL NO. EV889156520US**

## TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/002,603
Filing Date	October 30, 2001
First Named Inventor	Alexander Gaiger
Art Unit	1644
Examiner Name	Ronald B. Schwadron
Attorney Docket No.	210121.465C6-

ENCLOSURES (check all that apply)					
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration Extension of Time Requible Express Abandonment Request Information Disclosure Statement and Transmit Cited References Certified Copy of Priority Document(s) Response to Missing Paunder 37 CFR 1.52 or 1. Response to Missing Parts/Incomplete Application	□ Drawing(s) □ Request for Corrected Filing Receipt □ Licensing-related Papers □ Petition □ Petition to Convert to a Provisional Application □ Power of Attorney, Revocation, Change of Correspondence Address □ Declaration □ Statement under 37 CFR 3.73(b) □ Terminal Disclaimer Request for Refund □ CD, Number □ After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences □ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) □ Proprietary Information □ Status Letter □ Return Receipt Postcard □ Other Enclosure(s) (please identify below): Copy of Notice to Comply:				
SIGN	ATURE OF APPLICANT, ATTORNEY, OR AGENT				
Firm Name Seed In	tellectual Property Law Group PLLC  Customer Number  00500				
Signature Q	Un Vrvalo				
Printed Name Julie A.	Urvater, Ph.D., Patent Agent				
Date May 10	2007 Reg. No. 50,461				
CERTIFICATE OF TRANSMISSION/MAILING					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.					
Signature	·				
Typed or printed name	Date:				

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 953794\_1.DOC

EXPRESS MAIL NO: EV889156520US TATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO FILING DATE FIRST NAMED INVENTOR 10/002,603 10/30/2001 Alexander Gaiger 210121.465C6 3627 04/20/2007 **EXAMINER** SEED INTELLECTUAL PROPERTY LAW GROUP PLLC SCHWADRON, RONALD B 701 FIFTH AVE **SUITE 5400** ART UNIT SEATTLE, WA 98104 1644

Please find below and/or attached an Office communication concerning this application or proceeding.

MAIL DATE

04/20/2007

DELIVERY MODE

**PAPER** 

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

RECEIVED

SHORTENED STATUTORY PERIOD OF RESPONSE

30 DAYS

APR 2 3 2007

Seed Intellectual Property Law Group PLLC





### UNITED STATES $\Gamma^{-}$ `ARTMENT OF COMMERCE

U.S. Patent and Trauemark Office Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./	FILING DATE	FIRST NAMED INVENTOR I	ATTORNEY DOCKET NO.
CONTROL NO.		PATENT IN REEXAMINATION	

EXAMINER

ART UNIT PAPER

200704

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

#### **Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The sequence listed in Figure 8B is not identified by a SEO. ID. number.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Ron Schwadron, Ph.D. Primary Examiner Art Unit 1644

RONALD B. SCHWADRO: PRIMARY EXAMINE? GROUP 1880 (600



## **Notice to Comply**

Application No 10/002603	Applicant(s) Gaiger et al.	
Examiner	Art Unit	
Ron Schwadron,	1644	
Ph.D.		

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

×	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: SEE ENCLOSED COMMUNICATION
	oplicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment ecifically directing its entry into the application.
app	A statement that the content of the paper and computer readable copies are the same and, where plicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.25(d).
PL	EASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY